Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
| ▸ | AVPR1B | P47901 | 3/20 | 0.37 |
| ▸ | FPR2 | P25090 | 4/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5132127 | 0.94 | EPHX2 (0.46) | EPHX2HTR6TSHRNPSR1LMNA | |
| SCHEMBL5123711 | 0.94 | EPHX2 (0.53) | EPHX2HTR6TSHRAVPR1AAVPR1B | |
| SCHEMBL5128634 | 0.87 | EPHX2 (0.42) | EPHX2 | |
| SCHEMBL4111436 | 0.86 | BDKRB1 (0.41) | EPHX2TSHRNPSR1FPR2PROKR1 | |
| SCHEMBL4119445 | 0.84 | EPHX2 (0.49) | EPHX2 | |
| SCHEMBL3817162 | 0.80 | EPHX2 (0.41) | EPHX2HTR6AVPR1AAVPR1BFPR2 | |
| SCHEMBL5131959 | 0.80 | EPHX2 (0.53) | EPHX2HTR6TSHRFPR2PROKR1 | |
| SCHEMBL4123581 | 0.80 | NPSR1 (0.44) | TSHRNPSR1LMNA | |
| SCHEMBL5085809 | 0.78 | TSHR (0.54) | EPHX2TSHR | |
| SCHEMBL492268 | 0.76 | EPHX2 (0.41) | EPHX2HTR6AVPR1AAVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249128-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | EPHX2 1287/4885HTR6 526/4885TSHR 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.